Key result
Global ILD-associated HF prevalence rises ~166% from 1990 to 2021, peaking in older populations.
Why the study?
The burden of interstitial lung disease (ILD)-associated heart failure poses a significant challenge to prognosis, but its disease burden and future trends required characterization to inform targeted prevention and control strategies.
Observational
Absolute Event Rate: 1.41% vs 0.53%
The global burden of ILD-associated heart failure has significantly increased over the past three decades, highlighting the need for targeted prevention and management strategies, particularly in older populations and higher SDI regions.
BACKGROUND: The burden of interstitial lung disease (ILD)-associated heart failure (HF) poses a significant challenge to the prognosis of ILD patients. This study aimed to characterize the disease burden and analyse future trends of ILD-associated HF, offering valuable insights to inform targeted prevention and control strategies. METHODS: Data on the prevalence and years lived with disability (YLDs) of ILD-associated HF were retrieved from the Global Burden of Disease (GBD) database for the period 1990-2021. Trends in ILD-associated HF were evaluated using average annual percentage change (AAPC) and percentage change analyses. Future prevalence data were projected up to 2050 using predictive modelling. RESULTS: Globally, the number of patients with ILD-associated HF increased from 20,229 in 1990 to 104,059 in 2021, with the prevalence rising from 0.53 to 1.41 per 100,000 population. Prevalence rates were disproportionately higher in older populations, with individuals over 95 years experiencing a 17.78-fold increase over the study period. Additionally, a positive correlation was observed between higher socioeconomic development index (SDI) levels and ILD-associated HF prevalence. Among 204 countries, 71.1% exhibited an increasing trend in prevalence. However, Bayesian age-period-cohort (BAPC) modelling predicts a declining trend over the next 28 years. CONCLUSION: Over the past three decades, the global burden of ILD-associated HF has escalated, particularly among individuals aged over 65 and in regions with high SDI levels. These findings underscore the need for region-specific, personalized intervention strategies to mitigate disease progression and enhance the quality of life for ILD patients.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) conducted an observational in Interstitial lung disease-associated heart failure. Observation over time (2021 vs 1990) vs. 1990 baseline was evaluated on Global prevalence of ILD-associated HF per 100,000 population. Globally, the prevalence of interstitial lung disease-associated heart failure increased from 0.53 to 1.41 per 100,000 population between 1990 and 2021, with the highest burden in older populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: